Skip to main content
Erschienen in: Clinical and Experimental Medicine 2/2014

01.05.2014 | Original Article

Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo

verfasst von: Chunqiu Hao, Yumei Xie, Meijuan Peng, Li Ma, Yun Zhou, Yan Zhang, Wenzhen Kang, Jiuping Wang, Xuefan Bai, Pingzhong Wang, Zhansheng Jia

Erschienen in: Clinical and Experimental Medicine | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Activation of hepatic stellate cells (HSC) represents a critical event in fibrosis, and connective tissue growth factor (CTGF) plays a profibrotic activity and a key factor in the pathogenesis of tissue fibrosis. The current study aimed to determine whether lentivirus-mediated short hairpin RNA (shRNA)–targeted CTGF downregulates the CTGF expression and furthermore whether it suppresses the activation and proliferation of HSC in vitro and prevents liver fibrosis in vivo. HSC-T6 cells were treated with recombinant lentivirus carrying CTGF siRNA. Real-time PCR, Western blotting, MTT, and flow cytometry were performed to investigate the activation and proliferation of HSC-T6 cells in response to CTGF silence. CCl4-induced rats were received lentivirus containing CTGF siRNA by intraportal vein injection. Levels of liver fibrosis were assessed by biochemical and histopathologic examinations. Recombinant lentivirus containing CTGF siRNA could effectively and specifically downregulate the expression of CTGF in both HSC-T6 cells and CCl4-induced rats with liver fibrosis. Blockade of CTGF resulted in significant inhibition of HSC activation and proliferation with decrease in TIMPs, MMP2, MMP9, and collagen I, as well as increase in cells in S phase. Silencing CTGF expression with siRNA prevented liver fibrosis in CCl4-induced rat model. These findings indicated that CTGF plays a key role in the pathogenesis of liver fibrosis and lentiviral-mediated CTGF siRNA has the potential to be an effective treatment for liver fibrosis.
Literatur
2.
Zurück zum Zitat Povero D, Busletta C, Novo E, di Bonzo LV, Cannito S, Paternostro C, Parola M (2010) Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 25:1075–1091PubMed Povero D, Busletta C, Novo E, di Bonzo LV, Cannito S, Paternostro C, Parola M (2010) Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 25:1075–1091PubMed
3.
Zurück zum Zitat Arthur MJ (2002) Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 122:1525–1528PubMedCrossRef Arthur MJ (2002) Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 122:1525–1528PubMedCrossRef
4.
Zurück zum Zitat Hammel P, Couvelard A, O’Toole D, Ratouis A, Sauvanet A, Flejou JF, Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Levy P (2001) Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 344:418–423PubMedCrossRef Hammel P, Couvelard A, O’Toole D, Ratouis A, Sauvanet A, Flejou JF, Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Levy P (2001) Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 344:418–423PubMedCrossRef
5.
Zurück zum Zitat Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MD, Sands E, Suliman I, Trim N, Knorr A, Arthur MJ, Benyon RC, Iredale JP (2004) Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126:1795–1808PubMedCrossRef Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MD, Sands E, Suliman I, Trim N, Knorr A, Arthur MJ, Benyon RC, Iredale JP (2004) Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126:1795–1808PubMedCrossRef
6.
Zurück zum Zitat Gabele E, Brenner DA, Rippe RA (2003) Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci 8:d69–d77PubMedCrossRef Gabele E, Brenner DA, Rippe RA (2003) Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci 8:d69–d77PubMedCrossRef
7.
Zurück zum Zitat Bradham DM, Igarashi A, Potter RL, Grotendorst GR (1991) Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 114:1285–1294PubMedCrossRef Bradham DM, Igarashi A, Potter RL, Grotendorst GR (1991) Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 114:1285–1294PubMedCrossRef
8.
Zurück zum Zitat Chen XM, Qi W, Pollock CA (2009) CTGF and chronic kidney fibrosis. Front Biosci (Schol Ed) 1:132–141CrossRef Chen XM, Qi W, Pollock CA (2009) CTGF and chronic kidney fibrosis. Front Biosci (Schol Ed) 1:132–141CrossRef
9.
Zurück zum Zitat Dendooven A, Gerritsen KG, Nguyen TQ, Kok RJ, Goldschmeding R (2011) Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers 16:289–301PubMedCrossRef Dendooven A, Gerritsen KG, Nguyen TQ, Kok RJ, Goldschmeding R (2011) Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers 16:289–301PubMedCrossRef
10.
Zurück zum Zitat Hayashi N, Kakimuma T, Soma Y, Grotendorst GR, Tamaki K, Harada M, Igarashi A (2002) Connective tissue growth factor is directly related to liver fibrosis. Hepatogastroenterology 49:133–135PubMed Hayashi N, Kakimuma T, Soma Y, Grotendorst GR, Tamaki K, Harada M, Igarashi A (2002) Connective tissue growth factor is directly related to liver fibrosis. Hepatogastroenterology 49:133–135PubMed
11.
Zurück zum Zitat Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, Tsunematsu H, Li W, Miyagi T, Hosui A, Tatsumi T, Ishida H, Kanto T, Hiramatsu N, Kubota S, Takigawa M, Tomimaru Y, Tomokuni A, Nagano H, Doki Y, Mori M, Hayashi N (2011) Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 121:3343–3356PubMedCentralPubMedCrossRef Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, Tsunematsu H, Li W, Miyagi T, Hosui A, Tatsumi T, Ishida H, Kanto T, Hiramatsu N, Kubota S, Takigawa M, Tomimaru Y, Tomokuni A, Nagano H, Doki Y, Mori M, Hayashi N (2011) Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 121:3343–3356PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326–330PubMedCrossRef Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326–330PubMedCrossRef
13.
Zurück zum Zitat Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN et al (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696–699PubMedCrossRef Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN et al (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696–699PubMedCrossRef
14.
Zurück zum Zitat Huang G, Brigstock DR (2012) Regulation of hepatic stellate cells by connective tissue growth factor. Front Biosci 17:2495–2507CrossRef Huang G, Brigstock DR (2012) Regulation of hepatic stellate cells by connective tissue growth factor. Front Biosci 17:2495–2507CrossRef
15.
Zurück zum Zitat Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G (2010) Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 51:523–534PubMedCrossRef Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G (2010) Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 51:523–534PubMedCrossRef
16.
Zurück zum Zitat Mazzocca A, Dituri F, Lupo L, Quaranta M, Antonaci S, Giannelli G (2011) Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology 54:920–930PubMedCrossRef Mazzocca A, Dituri F, Lupo L, Quaranta M, Antonaci S, Giannelli G (2011) Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology 54:920–930PubMedCrossRef
17.
Zurück zum Zitat Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267–283PubMedCrossRef Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267–283PubMedCrossRef
18.
Zurück zum Zitat Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Fukui H (2002) Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36:850–860PubMedCrossRef Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Fukui H (2002) Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36:850–860PubMedCrossRef
19.
Zurück zum Zitat Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Thorgeirsson SS, Fukui H (2000) Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32:1248–1254PubMedCrossRef Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Thorgeirsson SS, Fukui H (2000) Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32:1248–1254PubMedCrossRef
20.
Zurück zum Zitat Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, Saisho H (1996) Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 24:1058–1062PubMedCrossRef Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, Saisho H (1996) Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 24:1058–1062PubMedCrossRef
21.
Zurück zum Zitat Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, Sato H, Seiki M, Ooshima A, Watanabe A (1995) Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 21:787–795PubMedCrossRef Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, Sato H, Seiki M, Ooshima A, Watanabe A (1995) Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 21:787–795PubMedCrossRef
22.
Zurück zum Zitat Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A (2005) Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 45:605–628PubMedCrossRef Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A (2005) Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 45:605–628PubMedCrossRef
23.
Zurück zum Zitat Li G, Xie Q, Shi Y, Li D, Zhang M, Jiang S, Zhou H, Lu H, Jin Y (2006) Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 8:889–900PubMedCrossRef Li G, Xie Q, Shi Y, Li D, Zhang M, Jiang S, Zhou H, Lu H, Jin Y (2006) Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 8:889–900PubMedCrossRef
24.
Zurück zum Zitat Uchio K, Graham M, Dean NM, Rosenbaum J, Desmouliere A (2004) Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis. Wound Repair Regen 12:60–66PubMedCrossRef Uchio K, Graham M, Dean NM, Rosenbaum J, Desmouliere A (2004) Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis. Wound Repair Regen 12:60–66PubMedCrossRef
25.
Zurück zum Zitat Li G, Li D, Xie Q, Shi Y, Jiang S, Jin Y (2008) RNA interfering connective tissue growth factor prevents rat hepatic stellate cell activation and extracellular matrix production. J Gene Med 10:1039–1047PubMedCrossRef Li G, Li D, Xie Q, Shi Y, Jiang S, Jin Y (2008) RNA interfering connective tissue growth factor prevents rat hepatic stellate cell activation and extracellular matrix production. J Gene Med 10:1039–1047PubMedCrossRef
26.
Zurück zum Zitat Kothapalli D, Grotendorst GR (2000) CTGF modulates cell cycle progression in cAMP-arrested NRK fibroblasts. J Cell Physiol 182:119–126PubMedCrossRef Kothapalli D, Grotendorst GR (2000) CTGF modulates cell cycle progression in cAMP-arrested NRK fibroblasts. J Cell Physiol 182:119–126PubMedCrossRef
27.
Zurück zum Zitat Furlong F, Crean J, Thornton L, O’Leary R, Murphy M, Martin F (2007) Dysregulated intracellular signaling impairs CTGF-stimulated responses in human mesangial cells exposed to high extracellular glucose. Am J Physiol Renal Physiol 292:F1691–F1700PubMedCrossRef Furlong F, Crean J, Thornton L, O’Leary R, Murphy M, Martin F (2007) Dysregulated intracellular signaling impairs CTGF-stimulated responses in human mesangial cells exposed to high extracellular glucose. Am J Physiol Renal Physiol 292:F1691–F1700PubMedCrossRef
28.
Zurück zum Zitat Croci S, Landuzzi L, Astolfi A, Nicoletti G, Rosolen A, Sartori F, Follo MY, Oliver N, De Giovanni C, Nanni P, Lollini PL (2004) Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res 64:1730–1736PubMedCrossRef Croci S, Landuzzi L, Astolfi A, Nicoletti G, Rosolen A, Sartori F, Follo MY, Oliver N, De Giovanni C, Nanni P, Lollini PL (2004) Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res 64:1730–1736PubMedCrossRef
29.
Zurück zum Zitat Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Luscher TF, Fujii T (1999) Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem 274:37461–37466PubMedCrossRef Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Luscher TF, Fujii T (1999) Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem 274:37461–37466PubMedCrossRef
Metadaten
Titel
Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo
verfasst von
Chunqiu Hao
Yumei Xie
Meijuan Peng
Li Ma
Yun Zhou
Yan Zhang
Wenzhen Kang
Jiuping Wang
Xuefan Bai
Pingzhong Wang
Zhansheng Jia
Publikationsdatum
01.05.2014
Verlag
Springer Milan
Erschienen in
Clinical and Experimental Medicine / Ausgabe 2/2014
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-013-0229-6

Weitere Artikel der Ausgabe 2/2014

Clinical and Experimental Medicine 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.